How Can Korea Grab Window Of Opportunity In AI Drug Development?
Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.
You may also be interested in...
South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.
Application of artificial intelligence to new drug development in South Korea, which has been lagging in this area, is poised to accelerate as the country moves to support and encourage the technology.